GCA
MCID: TMP003
MIFTS: 69

Temporal Arteritis (GCA)

Categories: Bone diseases, Cardiovascular diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Temporal Arteritis

MalaCards integrated aliases for Temporal Arteritis:

Name: Temporal Arteritis 57 12 53 54 59 15 73
Giant Cell Arteritis 57 12 76 53 54 59 37 43 44 15 73
Polymyalgia Rheumatica 57 12 76 59 37 55 43 44 15 73
Cranial Arteritis 57 53 54 73
Rhizomelic Pseudopolyarthritis 59 73
Horton Disease 76 59
Gca 57 53
Horton's Giant Cell Arteritis 53
Horton's Temporal Arteritis 53
Giant Cell Arteritis; Gca 57
Arteritis Temporalis 53
Arteritis Cranialis 53
Horton's Arteritis 53
Horton's Disease 12

Characteristics:

Orphanet epidemiological data:

59
giant cell arteritis
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Germany),1-5/10000 (United Kingdom),1-5/10000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
temporal arteritis:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Temporal Arteritis

NIH Rare Diseases : 53 Giant cell arteritis (GCA) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. GCA most commonly affects the arteries of the head (especially the temporal arteries, located on each side of the head), but arteries in other areas of the body can also become inflamed. The inflammation causes the arteries to narrow, resulting in poor blood flow. Signs and symptoms when arteries in the head are involved may include a throbbing headache on one side or the back of the head, tenderness of the scalp, flu-like symptoms, and/or problems with eyesight. Symptoms when other arteries are involved depend on the location of those arteries. The cause of GCA is still being studied, but it is thought to involve the immune system mistakenly attacking the artery walls. Several genetic and environmental factors may increase a person's risk to develop GCA. Complications of GCA may include permanent vision loss or a stroke, so treating the condition is important. Treatment may include corticosteroids and/or other medications that suppress the immune system. GCA may develop with or after another inflammatory disorder known as polymyalgia rheumatica, which occurs in about 40% to 50% of people with GCA. 

MalaCards based summary : Temporal Arteritis, also known as giant cell arteritis, is related to synovitis and miliary tuberculosis, and has symptoms including muscle weakness, angina pectoris and edema. An important gene associated with Temporal Arteritis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Prednisone and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include tongue, testes and skin, and related phenotypes are ptosis and nystagmus

MedlinePlus : 43 Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no single test to diagnose giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 54 Vasculitis is inflammation of blood vessels, which includes the veins, arteries, and capillaries. It occurs when the immune system mistakenly attacks a blood vessel. Vasculitis can also be caused by other immune system disease, an allergic reaction to medicines or toxins, and by certain blood cancers that trigger an immune system reaction. The resulting reduced blood flow can permanently damage the brain, spinal cord, peripheral nervous system, and other organs and tissue. Some forms of vasculitis affect a particular organ, whie others may affect many organs at the same time. Symptoms include headaches (especially a headache that doesn’t go away), fever, weight loss, confusion or forgetfulness leading to dementia, swelling of the brain, pain, vision problems, trouble speaking or understanding, muscle weakness and paralysis, and seizures. Some of the better understood vasculitis syndromes are temporal arteritis (also called giant cell arteritis or cranial arteritis--a chronic inflammatory disorder of large blood vessels) and Takayasu’s disease, which affects larger aortas and may cause stoke.

Wikipedia : 76 Giant-cell arteritis (GCA), also called temporal arteritis, is an inflammatory disease of blood vessels.... more...

Description from OMIM: 187360

Related Diseases for Temporal Arteritis

Diseases in the Temporal Arteritis family:

Juvenile Temporal Arteritis

Diseases related to Temporal Arteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 535)
# Related Disease Score Top Affiliating Genes
1 synovitis 30.6 CRP IL1RN IL6 TNF
2 miliary tuberculosis 30.5 IFNG TNF
3 vasculitis 30.4 APOH CCL2 CRP TNF
4 cold agglutinin disease 30.3 CRP IL6
5 polyarteritis nodosa 30.3 APOH CRP IL6
6 spondyloarthropathy 30.2 IFNG IL6 TNF
7 aortitis 30.2 CRP SMUG1
8 posterior scleritis 30.2 TNF TNFRSF10A
9 relapsing polychondritis 30.1 CRP IFNG IL6
10 proliferative glomerulonephritis 30.1 CCL2 IFNG IL6
11 lyme disease 30.1 CRP IL6 TNF
12 uveitis 30.0 CCL2 IFNG TNF
13 alopecia areata 30.0 IFNG IL1RN PTPN22 TNF
14 arteriovenous fistula 29.9 APOH IL6
15 chlamydia 29.9 CRP IFNG IL6 TNF
16 arteries, anomalies of 29.9 CCL2 CRP IL6 TNF
17 endocarditis 29.9 APOH CRP IL6 TNF
18 aortic aneurysm, familial abdominal, 1 29.9 CCL2 CRP IL6
19 microscopic polyangiitis 29.9 HLA-DRB1 TNF
20 bronchiolitis obliterans 29.8 IFNG IL6 TNF
21 meningitis 29.8 CCL2 CRP IFNG IL6 TNF
22 arteriosclerosis 29.8 CCL2 CRP IL6
23 cerebrovascular disease 29.8 CRP IL6 TNF
24 peripheral artery disease 29.8 CCL2 CRP IL6
25 psoriatic arthritis 29.8 CRP HLA-DRB1 IL6 PTPN22 TNF
26 vascular disease 29.7 APOH CCL2 CRP IL6 TNF
27 scleritis 29.7 CCL2 IFNG TNF
28 extrinsic allergic alveolitis 29.7 CCL2 CCL5 IL6
29 anca-associated vasculitis 29.7 HLA-DRB1 IL6 TNF
30 anterior uveitis 29.7 IL6 PTPN22 TNF
31 spondylitis 29.7 CRP IL1RN IL6 TNF
32 intermittent claudication 29.7 APOH CRP IL6
33 retinal vein occlusion 29.6 APOH CCL2 IL6
34 arthritis 29.6 CCL2 HLA-DRB1 IFNG IL1RN IL6 PTPN22
35 ischemic heart disease 29.6 CCL2 CRP IL6 TNF
36 colitis 29.6 IFNG IL6 TNF
37 chagas disease 29.6 CCL2 IFNG IL6 TNF
38 atherosclerosis susceptibility 29.6 CCL2 CRP IL6 TNF
39 q fever 29.5 IFNG IL6 TNF
40 bronchiolitis 29.5 CCL5 CRP IFNG IL6 TNF
41 rheumatic disease 29.5 APOH CRP HLA-DRB1 IFNG TNF
42 radiculopathy 29.5 CCL2 CCL5 IL6
43 peritonitis 29.5 CCL2 CRP IL6 TNF
44 myeloma, multiple 29.5 CRP IL6 SMUG1 TNF
45 infective endocarditis 29.5 APOH CRP IL6 TNF
46 diabetes mellitus 29.5 CRP HLA-DRB1 IFNG IL1RN IL6 PTPN22
47 pneumonia 29.5 CCL2 CCL5 CRP IL6 TNF
48 purpura 29.5 APOH CRP IL6 TNF
49 takayasu arteritis 29.5 CRP HLA-DRB1 IL6 TNF
50 ulcerative colitis 29.4 CRP IFNG IL6 TNF

Comorbidity relations with Temporal Arteritis via Phenotypic Disease Network (PDN): (show all 24)


Active Peptic Ulcer Disease Acute Cystitis
Aortic Valve Disease 1 Bronchitis
Cerebral Arteritis Chronic Myocardial Ischemia
Conn's Syndrome Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Ischemic Heart Disease
Mitral Valve Disease Nonarteritic Anterior Ischemic Optic Neuropathy
Optic Neuritis Osteoporosis
Polymyositis Premature Ovarian Failure 7
Rheumatoid Arthritis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Temporal Arteritis:



Diseases related to Temporal Arteritis

Symptoms & Phenotypes for Temporal Arteritis

Symptoms via clinical synopsis from OMIM:

57
Eyes:
blindness
retinal arteritis

Lab:
elevated sedimentation rate

Vascular:
temporal arteritis
giant cell arteritis
polymyalgia rheumatica (pmr)

Misc:
response to adrenal glucocorticoids


Clinical features from OMIM:

187360

Human phenotypes related to Temporal Arteritis:

59 32 (show top 50) (show all 59)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000508
2 nystagmus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000639
3 diplopia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000651
4 depressivity 59 32 frequent (33%) Frequent (79-30%) HP:0000716
5 hyperhidrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000975
6 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
7 muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0001324
8 sudden cardiac death 59 32 occasional (7.5%) Occasional (29-5%) HP:0001645
9 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
10 joint stiffness 59 32 hallmark (90%) Very frequent (99-80%) HP:0001387
11 optic atrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0000648
12 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
13 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
14 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
15 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
16 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
17 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
18 abnormality of the pleura 59 32 occasional (7.5%) Occasional (29-5%) HP:0002103
19 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
20 aortic dissection 59 32 occasional (7.5%) Occasional (29-5%) HP:0002647
21 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
22 ophthalmoparesis 59 32 frequent (33%) Frequent (79-30%) HP:0000597
23 visual field defect 59 32 occasional (7.5%) Occasional (29-5%) HP:0001123
24 anorexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002039
25 cerebral ischemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002637
26 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
27 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
28 amaurosis fugax 59 32 occasional (7.5%) Occasional (29-5%) HP:0100576
29 hematuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000790
30 diabetes insipidus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000873
31 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
32 visual loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0000572
33 conductive hearing impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000405
34 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
35 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
36 recurrent pharyngitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100776
37 meningitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001287
38 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
39 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
40 hepatic failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001399
41 arterial thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004420
42 headache 59 32 hallmark (90%) Very frequent (99-80%) HP:0002315
43 mediastinal lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100721
44 gastrointestinal infarctions 59 32 occasional (7.5%) Occasional (29-5%) HP:0005244
45 gangrene 59 32 occasional (7.5%) Occasional (29-5%) HP:0100758
46 glossitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000206
47 elevated erythrocyte sedimentation rate 59 32 frequent (33%) Frequent (79-30%) HP:0003565
48 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0011658
49 abdominal aortic aneurysm 59 32 occasional (7.5%) Occasional (29-5%) HP:0005112
50 hearing impairment 59 Occasional (29-5%)

UMLS symptoms related to Temporal Arteritis:


muscle weakness, angina pectoris, edema, pruritus, back pain, myalgia, chest pain, sciatica, muscle rigidity, exanthema, muscle cramp, muscle spasticity

MGI Mouse Phenotypes related to Temporal Arteritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.28 CCL2 CCL5 CRP IFNG IL1RN IL6

Drugs & Therapeutics for Temporal Arteritis

Drugs for Temporal Arteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
2 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Omega 3 Fatty Acid Phase 4
9
Infliximab Approved Phase 3,Phase 2 170277-31-3
10
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 83-43-2 6741
11
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 302-25-0
12
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 3,Not Applicable 2921-57-5
13
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 50-24-8 5755
14
Hydroxychloroquine Approved Phase 3 118-42-3 3652
15
Adalimumab Approved Phase 3 331731-18-1 16219006
16
Alendronate Approved Phase 3 66376-36-1, 121268-17-5 2088
17
Etanercept Approved, Investigational Phase 3 185243-69-0
18
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
19
Methotrexate Approved Phase 3,Phase 2 59-05-2, 1959-05-2 126941
20
Abatacept Approved Phase 3,Phase 2 332348-12-6 10237
21
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
22
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
25
Prednisolone hemisuccinate Experimental Phase 2, Phase 3,Phase 3,Not Applicable 2920-86-7
26 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Gastrointestinal Agents Phase 3,Phase 2,Not Applicable
28 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
29 Anti-Infective Agents Phase 3,Not Applicable
30 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Not Applicable
31 Prednisolone acetate Phase 2, Phase 3,Phase 3,Not Applicable
32 Methylprednisolone acetate Phase 2, Phase 3,Phase 3,Not Applicable
33 Antiemetics Phase 2, Phase 3,Phase 3,Not Applicable
34 Autonomic Agents Phase 2, Phase 3,Phase 3,Not Applicable
35 Neuroprotective Agents Phase 2, Phase 3,Phase 3,Not Applicable
36 Protective Agents Phase 2, Phase 3,Phase 3,Not Applicable
37 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Pharmaceutical Solutions Phase 3,Not Applicable
40 Antiparasitic Agents Phase 3
41 Antiprotozoal Agents Phase 3
42 Antimalarials Phase 3
43 Hydroxycholecalciferols Phase 3
44 Vitamins Phase 3
45 Calciferol Phase 3
46 Micronutrients Phase 3
47 Trace Elements Phase 3
48 Bone Density Conservation Agents Phase 3
49 Analgesics, Non-Narcotic Phase 3
50 Analgesics Phase 3

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
2 Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients Completed NCT01169597 Phase 4 prednisone
3 Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. Recruiting NCT03244709 Phase 4 Tocilizumab
4 Tocilizumab Plus a Short Prednisone Taper for GCA Recruiting NCT03726749 Phase 4 Tocilizumab;Prednisone
5 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
6 Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica Unknown status NCT01423591 Phase 3 infliximab;inactive powder
7 Hydroxychloroquine in Giant Cell Arteritis Completed NCT00430807 Phase 3 hydroxychloroquine/placebo
8 HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis Completed NCT00305539 Phase 3 adalimumab;placebo
9 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
10 Timed Release Tablet Prednisone in Polymyalgia Rheumatica Completed NCT00836810 Phase 2, Phase 3 Timed Release Tablet Prednisone;Prednisolone
11 Etanercept Treatment in the Early Course of Polymyalgia Rheumatica Completed NCT00524381 Phase 3 Etanercept (Enbrel);Sodium chloride (placebo)
12 An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Recruiting NCT03202368 Phase 3 Tocilizumab
13 Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA Recruiting NCT03600805 Phase 3 Sarilumab SAR153191;Sarilumab matching placebo;Prednisone;Prednisone matching placebo
14 Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Recruiting NCT03600818 Phase 3 Sarilumab SAR153191 (REGN88);Sarilumab-matching placebo;Prednisone;Prednisone-matching placebo;Prednisone
15 A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Recruiting NCT03263715 Phase 3 Tocilizumab Prefilled Syringe [Actemra];Placebos;Glucocorticoids
16 Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE Recruiting NCT02908217 Phase 3 Tocilizumab;Placebo
17 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Active, not recruiting NCT01791153 Phase 3 Tocilizumab;Prednisone;Tocilizumab Placebo;Prednisone Placebo;Corticosteroids;Methotrexate
18 Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS Active, not recruiting NCT03632187 Phase 3 Abatacept;Placebos
19 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis Not yet recruiting NCT03725202 Phase 3 Upadacitinib;Corticosteroid (CS)
20 Giant Cell Arteritis and Anakinra Trial Not yet recruiting NCT02902731 Phase 3 PLACEBO;ANAKINRA
21 Treatment With Leflunomide in Patients With Polymyalgia Rheumatica Not yet recruiting NCT03576794 Phase 3 Leflunomide 20 mg;Prednisolone
22 Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Terminated NCT02531633 Phase 2, Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone;Placebo to match prednisone
23 A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR Terminated NCT01821040 Phase 3 Lodotra®;Prednisone IR (immediate release)
24 A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) Withdrawn NCT03192969 Phase 3 Abatacept;Glucocorticoid Treatment
25 Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Withdrawn NCT02899026 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone /Prednisone placebo
26 Tocilizumab for Patients With Giant Cell Arteritis Completed NCT01450137 Phase 2 Tocilizumab + Glucocorticoids (GCs);Placebo + Glucocorticoids (GCs)
27 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Completed NCT00556439 Phase 2 Abatacept;Placebo
28 Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Completed NCT01910038 Phase 2 corticoids+ tocilizumab 8mg/Kg/4 weeks
29 Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis Completed NCT00004686 Phase 2 methotrexate;prednisone
30 Tocilizumab Effect iN pOlymyalgia Rheumatica Completed NCT01713842 Phase 2 TCZ
31 Study of Tocilizumab to Treat Polymyalgia Rheumatica Completed NCT01396317 Phase 2 Tocilizumab
32 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
33 Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Recruiting NCT03745586 Phase 1, Phase 2 Tocilizumab;Glucocorticoids
34 Ustekinumab for the Treatment of Giant Cell Arteritis Recruiting NCT02955147 Phase 1, Phase 2 Ustekinumab;Prednisone
35 Baricitinib in Relapsing Giant Cell Arteritis Recruiting NCT03026504 Phase 2 Baricitinib
36 Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Active, not recruiting NCT01740297 Phase 1, Phase 2 Talimogene laherparepvec;Ipilimumab
37 A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis Not yet recruiting NCT03765788 Phase 2 Prednisolone;Placebo to match Secukinumab, s.c.
38 Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) Not yet recruiting NCT03812302 Phase 2
39 Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis Not yet recruiting NCT03711448 Phase 2 prednisone treatment;prednisone and ustekinumab treatment
40 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Not yet recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
41 A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis Terminated NCT00076726 Phase 2 Infliximab
42 Delayed Release Prednisone in PMR Terminated NCT02702778 Phase 2 Delayed-Release (DR) Prednisone;Immediate Release (IR) Prednisone
43 A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica Terminated NCT01364389 Phase 2 AIN457;ACZ885;Prednisone;Placebo
44 MRI Superficial Temporal Artery Completed NCT00188448 Phase 1
45 Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Not yet recruiting NCT03656627 Phase 1 Nivolumab
46 Diagnostic Study of Temporal Arteritis Unknown status NCT01130857
47 Study of Circulating Microparticles in Giant Cell Arteritis Unknown status NCT02333708
48 Giant Cell Arteritis: Improving Use of Ultrasound Evaluation Unknown status NCT02523625
49 Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis Unknown status NCT00361192 Early Phase 1
50 Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease Unknown status NCT02857192 Not Applicable

Search NIH Clinical Center for Temporal Arteritis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: giant cell arteritis

Genetic Tests for Temporal Arteritis

Anatomical Context for Temporal Arteritis

MalaCards organs/tissues related to Temporal Arteritis:

41
Tongue, Testes, Skin, Brain, Spinal Cord, Eye, T Cells

Publications for Temporal Arteritis

Articles related to Temporal Arteritis:

(show top 50) (show all 2264)
# Title Authors Year
1
Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control study. ( 30066157 )
2019
2
Central retinal vein occlusion in temporal arteritis: red sign or red herring? ( 29361164 )
2018
3
Intravascular Large B-Cell Lymphoma Mimicking Temporal Arteritis. ( 29854538 )
2018
4
Refractory Giant Cell Arteritis Complicated by Vision Loss From Optic Atrophy and Maculopathy Associated With Pachymeningitis. ( 29059089 )
2018
5
Secondary Syphilis Mimicking Giant Cell Arteritis. ( 29561471 )
2018
6
Spectrum of Aortic Disease in the Giant Cell Arteritis Population. ( 29291886 )
2018
7
Increased expression of interleukin-22 in patients with giant cell arteritis. ( 28968695 )
2018
8
Imaging giant cell arteritis and Aortitis in contrast enhanced 18F-FDG PET/CT: Which imaging score correlates best with laboratory inflammation markers? ( 29362158 )
2018
9
A case of giant cell arteritis associated with a culture proven Coxiella burnetii aortitis. ( 29408476 )
2018
10
Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. ( 29961687 )
2018
11
Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis. ( 29394408 )
2018
12
Myocarditis in Giant Cell Arteritis Diagnosed With Fluorine 18-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography: Case Report and Review of the Literature. ( 29933325 )
2018
13
The potential for dual pathology in temporal arteritis. ( 29186538 )
2018
14
Dural arteriovenous fistula mimicking temporal arteritis. ( 30504098 )
2018
15
Three-Dimensional High-Resolution Black-Blood Magnetic Resonance Imaging for Detection of Arteritic Anterior Ischemic Optic Neuropathy in Patients With Giant Cell Arteritis. ( 30095558 )
2018
16
Giant Cell Arteritis Associated Arteritic Anterior Ischemic Optic Neuropathy: Sudden Vision Loss on the Contralateral Side of Headache. ( 30198237 )
2018
17
Combined bilateral ophthalmic artery occlusion & central retinal vein occlusion from presumed giant cell arteritis. ( 30148234 )
2018
18
Swept-Source Optical Coherence Tomography Angiography of an Amalric Choroidal Infarction in a Rare Presentation of Giant Cell Arteritis With Bilateral Corneal Edema. ( 30395679 )
2018
19
Non-infective endocarditis: Expanding the phenotype of giant cell arteritis. ( 29709695 )
2018
20
Giant cell arteritis presenting with ANCA-associated glomerulonephritis. ( 29542048 )
2018
21
The association of gout with incident giant cell arteritis in older adults. ( 29885976 )
2018
22
Co-Presentation of Giant Cell Arteritis and Granulomatosis with Polyangiitis: A Case Report and Review of Literature. ( 29872033 )
2018
23
Temporal headache and jaw claudication may be the key for the diagnosis of giant cell arteritis. ( 29680850 )
2018
24
Does herpes zoster predispose to giant cell arteritis: a geo-epidemiologic study. ( 29391771 )
2018
25
Giant cell arteritis and inflammatory bowel disease - Is there a connection? Results from a population-based study. ( 30217549 )
2018
26
Giant cell arteritis as unusual cause of critical arm ischemia. ( 30186996 )
2018
27
Lacrimal Gland Ischemia due to Giant Cell Arteritis. ( 30032795 )
2018
28
Giant cell arteritis presenting as bilateral anterior ischemic optic neuropathy: a biopsy-proven case report in Chinese patient. ( 30376812 )
2018
29
Simultaneous bilateral posterior ischemic optic neuropathy secondary to giant cell arteritis: a case presentation and review of the literature. ( 30541489 )
2018
30
Image Gallery: Bilateral juvenile temporal arteritis. ( 30318798 )
2018
31
Tracheal enlargement or Mounier-Kuhn syndrome in giant cell arteritis: a possible causal association with therapeutic implications. ( 30173269 )
2018
32
Orbitocerebral mucormycosis and intracranial haemorrhage: a role for caution with steroids in suspected giant cell arteritis. ( 30012677 )
2018
33
Simultaneous Presentation of Giant Cell Arteritis and Myelodysplastic Syndrome in an Elderly Japanese Man. ( 29780154 )
2018
34
Pericarditis among giant cell arteritis patients: From myth to reality. ( 29746000 )
2018
35
Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease? ( 29624864 )
2018
36
Biological treatments in giant cell arteritis & Takayasu arteritis. ( 29146018 )
2018
37
Temporal Arteritis Presenting as an Isolated Bilateral Abducens Nerve Palsy: A Rare Case of a 65-year-old Male. ( 30042918 )
2018
38
Bilateral scalp necrosis associated with temporal arteritis. ( 30260140 )
2018
39
Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis. ( 29759126 )
2018
40
Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. ( 29862043 )
2018
41
[18F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis-lessons from a vasculitis clinic. ( 29126277 )
2018
42
Case report: giant cell arteritis in a patient with carotid atherosclerosis - a diagnostic dilemma. ( 29915652 )
2018
43
Current and emerging diagnosis tools and therapeutics for giant cell arteritis. ( 29877748 )
2018
44
Should Antiviral/Anti-Varicella Zoster Virus Treatment Be Used in Patients With Giant Cell Arteritis? ( 29877905 )
2018
45
Incidence of cardiovascular events in polymyalgia rheumatica and giant cell arteritis amongst an Asian population: Propensity score matched cohort study. ( 29879315 )
2018
46
Arterial lesions in giant cell arteritis: A longitudinal study. ( 29880442 )
2018
47
Pathologic Markers Determining Prognosis in Patients With Treated or Healing Giant Cell Arteritis. ( 29890162 )
2018
48
Giant Cell Arteritis. ( 29924413 )
2018
49
Tongue Necrosis in Giant-Cell Arteritis. ( 29949496 )
2018
50
New headaches with normal inflammatory markers: an early atypical presentation of giant cell arteritis. ( 29950495 )
2018

Variations for Temporal Arteritis

Expression for Temporal Arteritis

Search GEO for disease gene expression data for Temporal Arteritis.

Pathways for Temporal Arteritis

Pathways related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CCL2 CCL5 CRP HLA-DRB1 IFNG IL1RN
2
Show member pathways
13.22 CCL2 CCL5 HLA-DRB1 IFNG IL1RN IL6
3
Show member pathways
13.17 CCL2 CCL5 IL6 PTPN22 TNF TNFRSF10A
4
Show member pathways
12.9 CCL2 CCL5 IFNG IL6 TNF
5
Show member pathways
12.85 CCL2 CCL5 IL6 TNF TNFRSF10A
6
Show member pathways
12.6 CCL2 CCL5 HLA-DRB1 IFNG IL6 TNF
7
Show member pathways
12.49 HLA-DRB1 IFNG IL6 TNF
8
Show member pathways
12.48 CCL2 IFNG IL6 TNF
9 12.4 CCL2 CCL5 IFNG IL1RN PTPN22 TNF
10
Show member pathways
12.24 CCL2 IFNG IL6 TNF
11 12.13 HLA-DRB1 IFNG IL6 TNF
12
Show member pathways
12.03 CCL2 CCL5 CRP IFNG IL6 SERPINA3
13 12 CCL2 IFNG TNF
14
Show member pathways
11.97 IFNG IL6 TNF
15
Show member pathways
11.96 CCL2 CCL5 IFNG IL6 TNFRSF10A
16
Show member pathways
11.95 IFNG IL6 TNF
17 11.9 IFNG IL6 TNF
18 11.89 CCL2 IL6 TNF
19 11.89 CCL2 IFNG IL6 TNF
20 11.84 CCL2 CCL5 IL6 TNF
21 11.81 CCL2 IL6 TNF
22 11.8 HLA-DRB1 IL6 TNF
23 11.79 IFNG IL6 TNF
24 11.67 IFNG IL6 TNF
25
Show member pathways
11.59 IFNG IL6 TNF
26 11.56 CCL2 CCL5 IL6 TNF
27 11.48 IFNG IL6 TNF
28 11.44 CCL2 IFNG TNF
29 11.42 CCL2 IFNG IL6 TNF
30 11.39 IFNG IL6 TNF
31 11.39 CCL2 CCL5 HLA-DRB1 IFNG IL6 TNF
32 11.34 CCL2 CCL5 IL1RN IL6 TNF
33 11.26 IFNG IL6 TNF
34 11.21 IFNG IL6 TNF
35 11.12 CCL2 CCL5 IL6 TNF
36 11.09 HLA-DRB1 IFNG IL6 TNF
37 10.96 CCL2 SERPINA3
38 10.95 CCL2 CCL5 IFNG IL1RN IL6 TNF
39 10.93 CRP IL6 TNF
40 10.87 CCL2 TNF

GO Terms for Temporal Arteritis

Cellular components related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 APOH CCL2 CCL5 CRP IFNG IL1RN
2 extracellular space GO:0005615 9.28 APOH CCL2 CCL5 CRP IFNG IL1RN

Biological processes related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 CRP IFNG IL6 PTPN22 TNF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 CCL2 CCL5 PTPN22 TNF
3 regulation of signaling receptor activity GO:0010469 9.85 CCL2 CCL5 IFNG IL1RN IL6 TNF
4 response to virus GO:0009615 9.82 CCL5 IFNG TNF
5 defense response to Gram-positive bacterium GO:0050830 9.81 CRP IL6 TNF
6 cellular response to lipopolysaccharide GO:0071222 9.81 CCL2 IL1RN IL6 TNF
7 neutrophil chemotaxis GO:0030593 9.8 CCL2 CCL5 IL1RN
8 cytokine-mediated signaling pathway GO:0019221 9.8 CCL2 CCL5 IL1RN IL6 TNF
9 cellular response to organic cyclic compound GO:0071407 9.79 CCL2 CCL5 TNF
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 CCL5 IFNG IL6
11 regulation of insulin secretion GO:0050796 9.78 CCL5 IFNG TNF
12 response to glucocorticoid GO:0051384 9.77 IL1RN IL6 TNF
13 positive regulation of interleukin-6 production GO:0032755 9.76 IL1RN IL6 TNF
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 CCL5 IL6 TNF
15 extrinsic apoptotic signaling pathway GO:0097191 9.71 IFNG TNF TNFRSF10A
16 monocyte chemotaxis GO:0002548 9.7 CCL2 CCL5 IL6
17 immune response GO:0006955 9.7 CCL2 CCL5 HLA-DRB1 IFNG IL1RN IL6
18 positive regulation of osteoclast differentiation GO:0045672 9.66 IFNG TNF
19 positive regulation of chemokine production GO:0032722 9.65 IL6 TNF
20 positive regulation of glial cell proliferation GO:0060252 9.65 IL6 TNF
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
22 protein kinase B signaling GO:0043491 9.65 CCL2 CCL5 TNF
23 macrophage chemotaxis GO:0048246 9.64 CCL2 CCL5
24 acute-phase response GO:0006953 9.63 CRP IL6 SERPINA3
25 humoral immune response GO:0006959 9.62 CCL2 IFNG IL6 TNF
26 positive regulation of neuroinflammatory response GO:0150078 9.59 IL6 TNF
27 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.57 IL1RN IL6
28 chronic inflammatory response to antigenic stimulus GO:0002439 9.55 IL1RN TNF
29 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
30 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 IFNG TNF
31 negative regulation of lipid storage GO:0010888 9.43 CRP IL6 TNF
32 lipopolysaccharide-mediated signaling pathway GO:0031663 9.26 CCL2 CCL5 PTPN22 TNF
33 inflammatory response GO:0006954 9.17 CCL2 CCL5 CRP IL1RN IL6 SERPINA3

Molecular functions related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.77 APOH CCL2 CCL5 CDK9 CRP IFNG
2 cytokine activity GO:0005125 9.1 CCL2 CCL5 IFNG IL1RN IL6 TNF

Sources for Temporal Arteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....